Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immucor -- Ignore unavailable to you. Want to Upgrade?

To: Mason Barge who wrote (202)	9/19/1998 9:04:00 AM
From: Thomas Kirwin	Respond to of 422

Connect the Dots - Gamma, Dominion, Immucor Mason & Technetx, If one connects the dots from Gamma to Dominion and Immucor there is clearly a contractual business relationship between the three as indicated in a press release issued by Gamma on April 1, 1998. Take a look! GAMMA BIOLOGICALS EXPANDS ReACTTTEST SYSTEM SALES BY NAMING EXCLUSIVE DISTRIBUTOR IN CANADA Contract covers new territory for Gamma HOUSTON, April 1, 1998------With the premarketing phase of the Gamma ReACTT Test System complete, Gamma Biologicals, Inc. (Amex: GBL) has named an exclusive distributor in Canada for this patented microcolumn gel technology designed for the rapid and labor-saving detection of red blood cell antibodies. Dominion Biologicals, Ltd., of Nova Scotia will hold exclusive rights to market ReACT and certain specialty products throughout Canada for an initial period of five years. Gamma selected Dominion, the Canadian market leader, because of its direct sales force. Although Gamma uses a direct sales force in the United States, the company has not had any sales representatives based in Canada. Gamma representatives who have Canadian customers will continue to service those accounts for traditional reagents and cell products. The agreement calls for Dominion to meet certain performance criteria over the life of the contract and any extensions. Total value of the initial five-year contract is more than $1 million, equivalent to about 6% of Gamma's fiscal 1997 revenues. "We've already shipped the first 11 ReACT systems to Dominion," reported David E. Hatcher, Gamma's chairman, president and chief executive officer. "Since receiving FDA approval in September 1997, we have placed - outright or through our reagent purchase plan - 147 systems, all of which are designed to use Gamma's disposable, prefilled test strips." To increase production of the ReACT test strips to commercial levels, Gamma installed a custom-built, multiunit machine that automates the filling, sealing and labeling. This new piece of equipment, now fully functioning, was designed and manufactured in Switzerland specifically for Gamma. "For our new fiscal year beginning today, we anticipate a significant positive impact on revenues and earnings from both the Dominion contract and the commercial production of ReACT test strips," Hatcher stated. "Such results depend, of course, on Dominion meeting anticipated performance levels; on Gamma's domestic sales force and international dealers selling both ReACT systems and other reagent products at planned volumes; and on other economic and business factors." Gamma Biologicals manufactures and sells a wide variety of highly refined and specialized testing products known as in-vitro diagnostic reagents. The company markets to blood donation centers (commonly called "blood banks"), transfusion departments of hospitals, medical laboratories and research institutions through a direct sales force and a distributor network to more than 50 countries. The company's common stock trades on the American Stock Exchange using the symbol GBL. Information about the company is available at gammabio.com. ### Some statements in this news release are forward-looking and involve certain risks and uncertainties, as stated. Investors should also review other uncertainties discussed in the company's latest Forms 10-Q and 10-K, on file with the Securities and Exchange Commission. CONTACT: David E. Hatcher - Chairman, President & CEO or Jimmie L. Turner - Executive Vice President & COO (713) 681-8481 Sally I. Evans, APR Public Relations Counsel

To: Mason Barge who wrote (202)	9/22/1998 9:02:00 PM
From: Thomas Kirwin	Read Replies (1) \| Respond to of 422

Pro-forma Napkin Math Mason, I know that you've been there and done that but I still like to project the pro-forma eps using napkin math after an acquisition. So here goes nothing! Assumption - Until the SEC 8-K is filed by Immucor it appears as though the acquisition will be accretive to earnings. Financing details are currently unavailable. There is no dilution as the deal is a cash tender offer. Gamma will contribute similar earnings as previously reported over the last two years. Gamma Net Income Average - $1,200,000 Immucor Basic Outstanding Shares - 8,111,300 EPS Increase - $1,200,000/8,111,300 = $0.15 Immucor TTM EPS - $0.25 Gamma Accretive EPS - $0.15 TOTAL Pro-forma EPS - $0.40 Share Price Valuation $0.40eps x 35pe = $14.00 Note - This exercise does not take into account the possibility of improved net earnings through the consolidation of redundant departments, increased ReACT sales, Gamma Technology deployment, etc. Go Immucor! Tom